Linong Ji
Peking University
Internal medicineEndocrinologySurgeryCross-sectional studyOdds ratioRandomized controlled trialPlaceboType 2 diabetesInsulinBody mass indexMetforminGlycemicHypoglycemiaPopulationType 2 Diabetes MellitusIn patientDiabetes mellitusMedicineBlood pressureGastroenterology
Publications 478
#1Suzanne V. Arnold (UMKC: University of Missouri–Kansas City)H-Index: 47
#2Kamlesh Khunti (University of Leicester)H-Index: 101
Last. Linong Ji (PKU: Peking University)H-Index: 53
view all 21 authors...
ABSTRACT null null Background null Micro- and macrovascular complications are a major cause of morbidity and mortality in people with type 2 diabetes (T2D). We sought to understand the global incidence rates and predictors of these complications. null null null Methods null We examined the incidence of vascular complications over 3 years of follow-up in the DISCOVER study—a global, observational study of people with T2D initiating second-line glucose-lowering therapy. Hierarchical Cox proportion...
#1Dongyang Liu (PKU: Peking University)H-Index: 10
Last. Linong Ji (PKU: Peking University)H-Index: 53
view all 10 authors...
Abstract null Background null PB-201, a partial, pancreas/liver-dual glucokinase activator, showed good tolerance and glycaemic effects in multinational studies. This study determined its optimal dose, safety, pharmacokinetics, and pharmacodynamics in Chinese patients with type 2 diabetes. null Methods null In this double-blind, randomised, four-period, crossover, phase 1 trial in China, conducted at the Peking University Third Hospital, adult patients with drug-naive type 2 diabetes were random...
#1Xingyun Zhu (PKU: Peking University)H-Index: 1
Last. Linong Ji (PKU: Peking University)H-Index: 53
view all 9 authors...
Purpose: The effect of physical activity on glycemic variability remains controversial. This meta-analysis aimed to assess the overall effect of physical activity treatment on glycemic variability in patients with diabetes. Methods: PubMed/MEDLINE, Embase, and Cochrane databases were searched for clinical trials that conducted in patients with type 1 diabetes mellitus and type 2 diabetes mellitus with reports of mean amplitude of glycemic excursion (MAGE), time in range (TIR), time above range (...
#1Keizo Kanasaki (Shimane University)H-Index: 40
#2Shen Qu (Tongji University)
Last. Linong Ji (PKU: Peking University)H-Index: 53
view all 7 authors...
Background null Safety and tolerability of glucose-lowering drugs is a key consideration for use in type 2 diabetes (T2D). We evaluated the safety and tolerability of the dipeptidyl peptidase-4 inhibitor linagliptin in Asian patients with T2D. null Research design and methods null This was a post-hoc, descriptive pooled analysis of 21 randomized, double-blind, placebo-controlled clinical trials of linagliptin in T2D patients lasting ≤52 weeks. We evaluated adverse events (AEs) and laboratory par...
#1Xixi Nan (CSU: Central South University)
#2Xia Li (CSU: Central South University)H-Index: 23
Last. Zhiguang Zhou (CSU: Central South University)H-Index: 55
view all 13 authors...
Background The detection of islet autoantibodies is essential for the accurate classification and diagnosis of diabetes mellitus (DM). The islet autoantibody distribution varies by age. However, screening strategies for DM patients with different onset ages remain lacking. Methods This cross-sectional study included 17 536 DM patients from 46 medical centers across China. The seroprevalence of glutamic acid decarboxylase autoantibody (GADA), insulinoma-associated-2 autoantibody (IA-2A), zinc tra...
#1Siqian GongH-Index: 6
#2Xueyao HanH-Index: 19
Last. Xiuting HuangH-Index: 2
view all 18 authors...
Last. Yingyao Chen (Fudan University)H-Index: 1
view all 7 authors...
INTRODUCTION To compare the cost-effectiveness of flash glucose monitoring versus self-monitoring of blood glucose/point of care testing (SMBG/POCT) in both patients with type 1 and patients with type 2 diabetes (T1D/T2D) receiving insulin therapy. METHODS The IQVIA CORE Diabetes Model (version 9.5) was used to project the lifetime costs and health outcomes of flash glucose monitoring and SMBG/POCT from a Chinese societal perspective. We considered both hospital and individual version flash gluc...
#1Fang Lyu (Chinese PLA General Hospital)
#2Xiaoling CaiH-Index: 17
Last. Linong JiH-Index: 53
view all 11 authors...
BACKGROUND Cardiovascular (CV) disease is the leading cause of morbidity and mortality in adults with type 2 diabetes (T2D). The aim of this study was to determine the CV risk in Chinese patients with T2D based on the 2019 European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD) guidelines on diabetes, pre-diabetes, and CV diseases. METHODS A total of 25,411 patients with T2D, who participated in the study of China Cardiometabolic Registries 3B study, we...
#1Xiaoming Zhang (PKU: Peking University)H-Index: 4
#2Yumei Wei (PKU: Peking University)H-Index: 17
Last. Huixia Yang (PKU: Peking University)H-Index: 37
view all 9 authors...
Pregnant women afflicted with gestational diabetes mellitus (GDM) and diabetes mellitus (DM) are prone to both maternal and neonatal complications. Due to this, it is of importance to sustain a str...
#1Fabrice Bonnet (University of Rennes)H-Index: 67
#2Hungta Chen (AstraZeneca)H-Index: 11
Last. Afrah Siddiqui (AstraZeneca)H-Index: 1
view all 14 authors...
AIMS Glycaemic control is a cornerstone of type 2 diabetes (T2D) management. We assessed factors associated with good long-term glycaemic control in patients with glycated haemoglobin (HbA1c) ≥7.0% at initiation of second-line glucose-lowering therapy, using data from DISCOVER, a global, prospective, 3-year observational study of patients with T2D. MATERIALS AND METHODS This analysis included patients with HbA1c ≥7.0% at baseline (initiation of second-line therapy). Multivariable regression mode...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.